Already, companies operating in the social media space — whether intended as an adverse event channel or not — have a responsibility to document and follow up with any potential adverse outcomes communicated through these forums.
According to the EU’s Volume 9A of The Rules Governing Medicinal Products, pharmaceutical companies are responsible for screening websites under their management for adverse events.
Although the FDA has yet to release updated social media guidance, companies operating in the US take a similar approach. Because companies already show responsibility for their own online content, it follows that several surveyed companies (32%) have developed their social media resources to serve as an additional adverse event-reporting channel.
The key behind using social media as an adverse event channel stems from unlocking its potential as a value-add for companies’ pharmacovigilance strategies.
Pour lire l’article paru dans pharmaphorum